Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
← catalyst calendarNCT06859099 · readout in 1,141 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
300estimated
Sites
49
Countries
Argentina, Brazil, Canada +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-01 | actual | When the study began enrolling |
| Primary completion | 2029-10-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-03 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Polyneuropathy, Inflammatory Demyelinating, Chronic
Intervention
- Drug: Riliprubart Prefilled Pen (PFP) — also filed as SAR445088
Primary outcome
what the primary-completion date above is the date OFNumber of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study period
measured Up to End of Study (approx. 4 years)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed